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and Al M. Best, Ph.D., for the Congenital Cytomegalovirus Collaborating Group*

abstract
background
From the Departments of Pediatrics (G.N.)
and Gynecological Sciences, Perinatology,
and Child Health (G.N., R.L.), La Sapienza
University, Rome; and the Department of
Pediatrics and Biostatistics, Medical College
of Virginia Campus, Virginia Commonwealth
University, Richmond (S.P.A., A.M.B.). Address reprint requests to Dr. Nigro at Via dei
Villini 35, 00161 Rome, Italy, or at nigrogio@
libero.it.
*Members of the Congenital Cytomegalovirus Collaborating Group are listed in
the Appendix.

Currently, there is no effective intervention for a primary cytomegalovirus (CMV) infection during pregnancy.
methods

We studied pregnant women with a primary CMV infection. The therapy group comprised women whose amniotic fluid contained either CMV or CMV DNA and who were
offered intravenous CMV hyperimmune globulin at a dose of 200 U per kilogram of maternal weight. A prevention group, consisting of women with a recent primary infection
before 21 weeks’ gestation or who declined amniocentesis, was offered monthly hyperimmune globulin (100 U per kilogram intravenously).

N Engl J Med 2005;353:1350-62.

results

Copyright © 2005 Massachusetts Medical Society.

In the therapy group, 31 women received hyperimmune globulin, only 1 (3 percent) of
whom gave birth to an infant with CMV disease (symptomatic at birth and handicapped
at two or more years of age), as compared with 7 of 14 women who did not receive hyperimmune globulin (50 percent). Thus, hyperimmune globulin therapy was associated with a significantly lower risk of congenital CMV disease (adjusted odds ratio,
0.02; 95 percent confidence interval, ¡∞ to 0.15; P<0.001). In the prevention group,
37 women received hyperimmune globulin, 6 (16 percent) of whom had infants with
congenital CMV infection, as compared with 19 of 47 women (40 percent) who did not
receive hyperimmune globulin. Thus, hyperimmune globulin therapy was associated
with a significantly lower risk of congenital CMV infection (adjusted odds ratio, 0.32; 95
percent confidence interval, 0.10 to 0.94; P=0.04). Hyperimmune globulin therapy significantly (P<0.001) increased CMV-specific IgG concentrations and avidity and decreased natural killer cells and HLA-DR+ cells and had no adverse effects.
conclusions

Treatment of pregnant women with CMV-specific hyperimmune globulin is safe, and
the findings of this nonrandomized study suggest that it may be effective in the treatment and prevention of congenital CMV infection. A controlled trial of this agent may
now be appropriate.
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c

ytomegalovirus (cmv) infection is
a common and serious infection occurring in approximately 1 percent of all neonates.1-3 Congenital CMV infection is symptomatic in about 10 percent of the infected neonates and
is associated with clinically significant neurologic
sequelae in almost half of them. In addition, neurologic defects will eventually develop in 8 to 13 percent of neonates with asymptomatic infection.1-3
Among women with a primary infection during
pregnancy, the rate of fetal infection is approximately 40 percent.1,3,4 Although prenatal diagnosis of
congenital infection is possible, no prenatal therapy is currently available.
Following the favorable outcome of the infusion of CMV-specific hyperimmune globulin in a
fetus with symptomatic CMV infection,5 we performed a prospective study of hyperimmune globulin for the treatment or prevention of fetal CMV
infection.

methods
patients and protocol

A prospective study was performed from 1995 to
2003. Pregnant women who had a primary CMV
infection during or a few months before pregnancy were eligible, as were those who had undergone
amniocentesis that revealed CMV in amniotic fluid.
Given the likely safety of hyperimmune globulin, the
efficacy of immune globulin in animal models, and
the off-protocol availability of hyperimmune globulin, none of three ethics committees approved the
use of a randomized protocol but did approve the
administration of hyperimmune globulin in pregnant women with a confirmed primary CMV infection who had provided written informed consent.
We enrolled 157 pregnant women with primary
CMV infection in eight Italian cities (127 in Rome,
17 in Genoa, 8 in Perugia, and 1 each in five other
cities) (Fig. 1). Serologic testing was initiated by obstetricians, who routinely screened their patients
and then referred women for inclusion in the study.
A total of 148 women with no symptoms were identified on the basis of serologic screening, 8 women were identified on the basis of serologic testing
after an illness compatible with CMV infection,
and 1 woman was identified on the basis of serologic testing conducted after fetal ultrasonography
showed abnormal results. All eligible subjects were
enrolled. After enrollment, clinical, ultrasonograph-
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ic, immunologic, and virologic evaluations were performed monthly.
Serologic testing was performed on serum samples obtained at the first obstetrical visit and every
one to three months thereafter (mean, six weeks).
Primary infection was defined by seroconversion
in 131 women who were previously CMV-seronegative, by the presence of CMV-specific IgM antibodies in 4 women, and by the presence of CMV-specific
IgM antibodies and very low but increasing concentrations of CMV-specific IgG antibodies with very
low CMV-specific IgG avidity (no more than 25 percent) in 22 women. The four women with CMV-specific IgM antibodies (identified at six, six, seven, and
nine weeks of pregnancy) had increasing concentrations of CMV-specific IgG antibodies and increasing CMV-specific IgG avidity and may have become
infected up to three months before conception.
Pregnant women were placed in one of two
groups. The therapy group consisted of pregnant
women who had had a primary infection more than
6 weeks before enrollment who were offered amniocentesis as soon as safely feasible (usually at
20 weeks’ gestation or more). If the amniotic fluid contained either CMV DNA on the basis of a polymerase-chain-reaction (PCR) assay or CMV on
the basis of culture results, intravenous hyperimmune globulin was offered at a dose of 200 U per
kilogram of maternal weight. Additional intravenous doses and intra–umbilical-cord or intraamniotic doses (400 U per kilogram of fetal weight)
were used only in the event of ultrasonographic evidence of persistent fetal involvement. Women with
CMV-positive amniotic fluid who declined to receive
hyperimmune globulin infusions were followed as
a comparison group. A total of 79 women underwent amniocentesis, 24 of whom had no evidence
of CMV in amniotic fluid. These 24 women were
ineligible for the study, but their infants were evaluated at birth.
The prevention group comprised women who
had not undergone amniocentesis before or at enrollment. Reasons for not undergoing amniocentesis were a primary infection within 6 weeks before enrollment and a pregnancy of less than 20
weeks’ gestation (making the detection of CMV
in amniotic fluid unlikely) or a woman’s declining
to undergo the procedure, regardless of the interval between a primary infection and enrollment.
All women were offered intravenous hyperimmune
globulin at a dose of 100 U per kilogram every
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181 Pregnant women identified
with confirmed primary CMV
infection

79 Underwent amniocentesis
before or at enrollment and >6 wk
after maternal seroconversion

55 Women with
CMV-positive
amniotic fluid enrolled

31 Elected to
receive
hyperimmune
globulin
(200 U/kg)

14 Elected not
to receive
hyperimmune
globulin

102 Enrolled who did not
undergo amniocentesis

37 Elected to receive
hyperimmune globulin
(100 U/kg) monthly
until delivery

24 Women with
CMV-negative
amniotic fluid ineligible

10 Elected to have
an abortion, no
hyperimmune
globulin

37 Gave birth

65 Elected not to
receive hyperimmune
globulin

47 Gave birth

18 Had an
abortion

Figure 1. Enrollment and Outcomes.

month until delivery. Monthly treatment was selected for this group because of the unknown infection status of their fetuses and thus the desire
to sustain antibody concentrations until delivery.
Because of the use of multiple doses, a lower dose
was selected to reduce costs. Pregnant women who
declined to receive hyperimmune globulin were
used as a comparison group.
Twenty-eight women (10 in the therapy group
and 18 in the prevention group), none of whom received hyperimmune globulin, were excluded from
follow-up when their pregnancies were aborted
(27 elective and 1 spontaneous). The rate of infection among the fetuses of the 18 women who aborted in the prevention group was not determined.
Neonatal evaluations included testing of urine
for CMV by two weeks of age; physical examination; blood-cell and platelet count; measurement
of aminotransferase, bilirubin, and creatinine concentrations; ophthalmoscopy; cerebral and abdominal ultrasonography; and brain-stem auditory
evoked responses. Among fetuses with suspected
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neurologic involvement, cerebrospinal fluid was obtained and electroencephalography, cerebral computed tomography, and magnetic resonance imaging were performed.
Symptomatic congenital CMV disease was defined by fetal or infant death or by neurologic involvement, including microcephaly (head circumference below the 5th percentile for gestational
age6), periventricular calcifications, cerebral dysplasias, seizures in an infant with CMV DNA in cerebrospinal fluid, ventricular and subependymal abnormalities, chorioretinitis, or auditory impairment.
Intrauterine growth restriction was defined by head
and abdominal circumferences that were below the
10th percentile for fetuses of similar age.7 CMV disease at two years of age or older was defined by
mental retardation (IQ below 70) or motor delay, or
both, and auditory or visual impairment. The Gesell,
Bayley, and Stanford–Binet scales were used for
evaluation. During the first two years of life, the children’s hearing was assessed by brain-stem auditory evoked responses. The threshold for normal hear-
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Table 1. Baseline Characteristics of the Therapy and Prevention Groups.*
Characteristic

Therapy Group (N=45)
Received HIG
(N=31)

No HIG
(N=14)

Maternal age at enrollment (yr)
Median

Prevention Group (N=84)

P Value†

Received HIG
(N=37)

No HIG
(N=47)

0.72

P Value†
0.32

29

27

30

29

25–32

26–32

28–33

27–32

1

0

0

0

Identified by maternal screening

27

14

36

43

Identified by maternal symptoms

3

0

1

4

2

2

0

0

12

11

14

20

8–15

9–18

8–16

14–26

15

7

NA

NA

NA

NA

Interquartile range
No. of primary maternal infections
Identified by ultrasonography

No. of primary maternal infections identified by IgM
antibodies alone

0.21

Wk of gestation at maternal infection‡
Median
Interquartile range
No. of fetuses with ultrasonographic evidence
of disease

0.79

Copies of CMV DNA in amniotic fluid (¬104)
Median
Interquartile range

By culture alone
By PCR and culture

Interquartile range

<0.01

17

28

NA

NA

1–37

13–85

NA

NA

NA

NA

11

5

19

NA

16–23

NA

0.47
3

0

17

9

24

NA

22–27

NA

Wk of gestation for HIG administration
Median

0.92

NA

Doses of HIG per woman
Interquartile range
No. of women given intra–umbilical-cord or
intraamniotic HIG (or both)

NA

5

NA

1–1

NA

4–6

NA

9

NA

NA

NA

21

23

NA

NA

19–25

20–32

NA

NA

Fetal infection identified (wk of gestation)
Median
Interquartile range

0.14

Time between maternal infection and HIG administration (wk)
Median
Interquartile range

13

NA

10–15

NA

Interquartile range

NA
NA

NA

Time between fetal diagnosis and HIG administration (wk)
Median

NA

1

NA

NA

NA

NA

Median

ND

0.15

No. of women with CMV-positive amniotic fluid
By PCR alone

0.58

0.38

NA
6

NA

5–9

NA

NA

NA

2

NA

NA

NA

1–4

NA

NA

NA

* HIG denotes hyperimmune globulin, and NA not applicable.
† Groups were compared by Fisher’s exact test or by Wilcoxon’s rank-sum test.
‡ When the weeks of gestation at the time of maternal infection were known only as a range, the average of the end points of the range was used
to estimate the time of maternal infection.
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10

9–16
11–15
10–18

8–21
14
4–11
8–19

7

8

9

10

11

12

13

4–11

4

10–21

11–25

3

6

20–24

2

5

7–12

1

www.nejm.org

22 IV
25 IV+IA

23 IV

24 IV
30 IV+IA

27 IV
30 IV+IA

Ventriculomegaly, intestinal echodensities

IUGR

IUGR

IUGR

None

None

None

None

IUGR, microcephaly, periventricular calcifications, lissencephaly, thrombocytopenic purpura

None

None

None

None

None

None

None

None

Signs and Symptoms at Birth

None

None

None

None

Severe mental and motor retardation:
not able to speak or stand

None

None

None

None

None

None

None

None

Disease at ≥2 Yr of Age

of

IUGR, microcephaly, periventricular
echodensities, ventriculomegaly,
hepatosplenomegaly

IUGR, pyelectasis, intestinal echodensities

IUGR

Ventriculomegaly, periventricular echodensities

IUGR

Hepatic echodensities

Pyelectasis, megaloureter

IUGR

Ventriculomegaly, ascites, hepatosplenomegaly

Possible Ultrasonographic Evidence
of Fetal Involvement

new england journal

23 IV
28 IV+IA+IC
33 IV+IA+IC

20 IV
36 IV+IA

28 IV
34 IV+IA

29 IV
33 IV+IA

25 IV

21 IV

33 IV

33 IV

23 IV
25 IV
30 IV+IA

wk of gestation and route

Mother–Infant Maternal Time
HIG
Pair
of Seroconversion Administered

Table 2. Outcomes among Children Born to Women with CMV-Infected Amniotic Fluid in the Therapy Group and Ultrasonographic Evidence of Fetal CMV Disease.*
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<9

5–14

21

22

None

None

None

None

None

None

None

23 IV

18 IV
24 IV+IA
29 IV+IA

Periventricular and hepatic echodensities

Ventriculomegaly

IUGR, cardiomegaly, splenomegaly

IUGR

Ascites, hepatomegaly

IUGR, microcephaly, ventriculomegaly,
intestinal echodensities, hepatomegaly, pyelectasis

IUGR

Intestinal and hepatic echodensities

Periventricular and intestinal echodensities, ventriculomegaly

Periventricular cysts and calcifications,
cerebral and cerebellar atrophy, retinitis

Microcephaly, periventricular calcifications, chorioretinitis, microphthalmia, bilateral hypoacusis

IUGR, cerebral atrophy, ventriculomegaly, hemiparesis

IUGR, periventricular calcifications,
liver disease, thrombocytopenic
purpura

Intrauterine death, CMV inclusions in
brain, kidneys, liver, and adrenal
glands

IUGR, microcephaly, periventricular calcifications, pyelectasis, liver disease,
thrombocytopenic purpura, postnatal death

IUGR, seizures (CMV DNA in cerebrospinal fluid), pneumonia, esophageal atresia

None

None

* HIG denotes hyperimmune globulin, IV intravenous, IA intraamniotic, IUGR intrauterine growth restriction, and IC intra–umbilical cord.

18–26

18

20

7

17

5

<8

16

19

<6
11–19

15

10–15

14

Mental and motor retardation: able to
speak a few words, not able to walk

Mental retardation (IQ <70): able to
speak a few words; unilateral neurisensorial hearing loss (right ear, 30
dB; left ear, 90 dB)

Mental retardation (IQ <70): able to
speak a few words; severe left hemiparesis (persistent at 8 yr); seizures

Mental and motor retardation (IQ <70):
able to speak a few words, not able
to walk

Not applicable

Not applicable

Seizures, hypotonia, right strabismus
and right-arm hypotrophy, ventriculomegaly and left cerebral hypotrophy

None

None

passive immunization against cmv during pregnancy
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ing was defined as 0 to 20 dB. Abnormal responses
were defined as mild (threshold, 21 to 45 dB), moderate (threshold, 46 to 70 dB), or severe (threshold,
at least 71 dB).
Each neonate was evaluated by a neonatologist,
and follow-up of all neonates was done by a single
physician.
cmv hyperimmune globulin

CMV hyperimmune globulin (Cytotect Biotest) has
a half-life of approximately 22 days, has been used
safely in other studies, and has antiviral and immunomodulatory effects.8-12 The mean titer of IgG antibodies against CMV glycoprotein B was 1:409,600,
and the mean IgG avidity was 75.9 percent. The infusion rate was 25 U per minute for 30 minutes and
then 50 U per minute until the calculated dose was
administered.

of

medicine

er cells), CD19+ B cells, and HLA-DR+ cells (activated lymphocytes, monocytes, and macrophages)
in blood were determined by flow cytometry.15,16
statistical analysis

Fisher’s exact test or Wilcoxon’s rank-sum test was
used for univariate analysis. Where appropriate, a
t-test was used on log-transformed data. An exact
logistic-regression analysis determined the factors associated with congenital infection or disease
(LogXact, version 4.0.2, Cytel Software). Using the
methods of Hosmer and Lemeshow, we evaluated
unadjusted odds ratios for potential inclusion in a
model.17 All those with an initial P value of less than
0.2 were included in the multivariate model.

results
therapy group

virologic methods

CMV was isolated by means of a shell vial. CMV
DNA was detected with the use of DNA extraction
and nested PCR.13 To determine the number of
genomic copies, competitive quantitative PCR was
performed with the use of CMV-ibridoquant (Amplimedical Bioline).
antibody detection

CMV-specific IgG and IgM antibodies were detected by an enzyme immunoassay kit (Radim). Duplicate serum samples were tested. Antibody concentrations (in units per milliliter) were calculated from
a calibration curve. CMV-specific IgG avidity was
measured with a kit from Bouty (Sesto). On the basis of published data and data from the manufacturer, avidities of less than 25 percent indicated an
infection within the previous three months.14
immunologic studies

Immunologic studies were performed in a subgroup of women who received hyperimmune globulin, before and after infusions, and in untreated
women at enrollment and after two months. The
cytotoxic activity of natural killer cells in response
to CMV-infected cells was determined on K562
cells labeled with chromium-51 by means of a fourhour 51Cr-release assay and was expressed as a specific percentage of cytotoxicity at various effectorto-target ratios (100:1, 50:1, 25:1, and 12.5:1).15
The percentage and number of CD3+ T cells, CD4+
(helper–inducer) T cells, CD8+ cells (cytotoxic suppressor lymphocytes), CD16+56+ cells (natural kill-
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The therapy group consisted of 31 women who received at least one infusion of hyperimmune globulin within 1 to 9 weeks (mean, 3.2 weeks) after the
diagnosis of fetal infection by amniocentesis and
14 women who declined to receive hyperimmune
globulin. The baseline variables in Table 1 were similar in the two subgroups of women. Because of ultrasonographic evidence of persistent fetal disease,
nine women (29 percent) received one or two additional intravenous infusions two to six weeks apart
and intra–umbilical-cord or amniotic infusions of
hyperimmune globulin or both (Tables 1 and 2).
Of the 31 women receiving hyperimmune globulin in the therapy group (15 of whom were carrying a fetus with ultrasonographic evidence of CMV
infection), only 1 delivered an infant with CMV disease, whereas 7 of 14 women who did not receive
hyperimmune globulin had affected infants. For infants with ultrasonographic evidence of disease before birth, the signs and symptoms of fetal disease,
disease at birth, and outcome at two years of age or
older are shown in Table 2. Each infant with a symptomatic infection at birth had disease at two years
of age, and each had ultrasonographic evidence of
fetal disease. No infant without ultrasonographic
evidence of fetal disease had symptoms at birth or
subsequently had sequelae.
Table 3 lists potential predictors of congenital
disease among mothers in the therapy group. A
logistic-regression model showed that two predictors were associated with a significantly reduced or
increased risk of congenital disease. These were receipt of hyperimmune globulin (adjusted odds ra-
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Table 3. Univariate and Adjusted Multivariate Logistic-Regression Analysis of Possible Predictors of Symptomatic
Congenital CMV Disease in the Therapy Group.*
Symptomatic Asymptomatic
Group
Group
(N=8)
(N=37)

Predictor

Univariate
P Value†

Multivariate
P Value‡

No. of infants whose mothers received HIG

1

30

<0.001

<0.001

No. of fetuses with ultrasonographic evidence
of disease before HIG therapy

8

14

0.002

<0.001

0.03

0.40

0.44

NI

0.45

NI

0.33

NI

No. of copies of CMV DNA in amniotic fluid (¬104)
Median

29.0

Interquartile range

5.5

21–92

1–36

Identified by ultrasonography

0

1

Identified by maternal screening

8

33

Identified by maternal symptoms

0

3

26

29

25–31

26–33

No. of primary infections

Maternal age at enrollment (yr)
Median
Interquartile range
Weeks of gestation at maternal infection§
Median

9

12

7–15

10–16

No. of women receiving intra–umbilical-cord or
intraamniotic HIG (or both)

1

8

1.0

NI

No. of infants who shed CMV at birth

8

31

0.58

NI

Interquartile range

* HIG denotes hyperimmune globulin, and NI not included in multivariate model.
† Either Fisher’s exact test or Wilcoxon’s rank-sum test was used for univariate comparisons.
‡ Exact logistic regression was used for the multivariate comparison.
§ When the weeks of gestation at the time of maternal infection were known only as a range, the average of the end points
of the range was used to estimate the time of maternal infection.

tio, 0.02; 95 percent confidence interval, ¡∞ to
0.15; P<0.001) and the presence of fetal disease
(adjusted odds ratio, 60.0; 95 percent confidence
interval, 5.5 to ∞; P<0.001), respectively. We repeated the logistic-regression model after excluding data on seven women whose diagnosis of primary infection was based solely on the presence
of CMV-specific IgM antibodies in their serum or
whose infants were not infected at birth. After
these exclusions, the receipt of hyperimmune globulin remained a significant predictor of a reduced
risk of neonatal disease (adjusted odds ratio, 0.03;
95 percent confidence interval, ¡∞ to 0.27; P=0.001)
and the presence of fetal disease remained a significant predictor of an increased risk (adjusted odds
ratio, 42.0; 95 percent confidence interval, 38.8 to
∞; P=0.001).
n engl j med 353;13

prevention group

The prevention group consisted of 37 women treated with monthly infusions of hyperimmune globulin 2 to 11 weeks (mean, 6.6) after presumed seroconversion; the number of infusions ranged from
2 to 7 (mean, 4.8). Five women missed infusions in
the third trimester. Also in this group were 47 pregnant women who did not receive hyperimmune
globulin. Of the 37 women who received hyperimmune globulin, 6 (16 percent) had infants with congenital infection. This rate was significantly lower
(P=0.02) than the 40 percent rate among the women who did not receive hyperimmune globulin (19
of 47).
Significantly associated with the receipt of hyperimmune globulin was a younger gestational age
at maternal infection, as compared with that among
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untreated women (Table 1). This occurred because
women who declined to undergo amniocentesis
were also more likely to decline hyperimmune globulin therapy. Women who were at 21 weeks of gestation or more at infection constituted 47 percent
of the women declining hyperimmune globulin but
only 13 percent of those receiving hyperimmune
globulin. Thus, the prevention group contained two
subgroups, those infected before 21 weeks’ gestation (when amniocentesis was less likely to be predictive) and those infected at 21 weeks’ gestation or
more but who declined amniocentesis. The difference in infection rates between these two groups
was not significant (P=0.20) (Table 4).
A logistic-regression model identified only one
predictor associated with a significant reduction
in the risk of congenital infection (Table 4) — receipt
of hyperimmune globulin (adjusted odds ratio,
0.32; 95 percent confidence interval, 0.10 to 0.94;
P=0.04). For women receiving hyperimmune globulin, there was no association between congenital
infection and the average number of doses of hyperimmune globulin received, gestational age at the
time of treatment, or the interval between infection
and receipt of hyperimmune globulin (Table 4).
In the prevention group, three women who did
not receive hyperimmune globulin became infected at 9, 10, and 18 weeks’ gestation, and gave birth
to infants with severe symptomatic infections. None
of the infants born to women who received hyperimmune globulin had symptoms at birth. There was
no significant difference in the rates of symptomatic infection between infants of treated women and
infants of untreated women in the prevention group.
Finally, we considered all women. In the prevention group, 47 women did not receive hyperimmune globulin, 19 of whom had infected neonates; in the therapy group, 55 women (including
10 who had an abortion) either did not receive hyperimmune globulin or received it after CMV disease was diagnosed in their fetus and 24 women
had CMV-negative amniotic fluid, 3 of whom had
infected but asymptomatic infants. These 126 women had a mean (±SD) gestational age at infection
of 14.3±7 weeks, and 56 percent (71 women) had
infected newborns. This rate was significantly higher (odds ratio, 0.15; 95 percent confidence interval, 0.06 to 0.38; P<0.001) than the 16 percent rate
(6 of 37) among women who received hyperimmune globulin, who were at a mean of 13.2±5.5
weeks of gestation at infection. Overall, CMV disease occurred in 28 percent (10 of 36) of the infants
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infected in utero whose mothers had a mean gestational age at infection of 16±9 weeks and who did
not receive hyperimmune globulin. This rate was
significantly higher (odds ratio, 0.07; 95 percent
confidence interval, 0.01 to 0.60; P=0.003) than the
2.7 percent rate among the infants of women who
received hyperimmune globulin (in the prevention
and therapy groups) and who had a mean gestational age at infection of 14±4 weeks; in this group,
CMV disease developed in only 1 of 37 infants infected in utero.
immunologic studies

We performed immunologic assays in women available for follow-up evaluations in Rome. Treatment
with hyperimmune globulin in prevention or therapy
doses was significantly associated with increased
CMV-specific IgG concentrations and IgG avidity
in serum after infusions (measured within 30 minutes after infusion in 24 patients and within six days
in 8 patients) to values similar to those present at
delivery (Table 5). Women receiving hyperimmune
globulin had CMV-specific IgG concentrations and
avidities at delivery similar to those among untreated women (Table 5).
The number and percentage of immune cells
were measured at enrollment and about eight
weeks after hyperimmune globulin infusion in 26
women and at enrollment and eight weeks later
in 21 untreated women. There were no significant
changes in values in the untreated women. Women who received hyperimmune globulin had a significant decrease of approximately 33 percent of
the percentage of the total natural killer cells and
HLA-DR+ cells and of the natural killer cell activity
and a 40 percent decrease in the absolute number
of HLA-DR+ and natural killer cells but no significant changes in CD3+, CD4+, CD8+, or CD19+ responses.
adverse events

No adverse events were associated with hyperimmune globulin infusions.

discussion
Our observations are consistent with the natural
history of CMV infection and pregnancy. For women infected before conception (who are seropositive), the rate of transmission of CMV from mother
to fetus usually ranges from 0.5 to 2 percent.1,18
However, for women with a primary infection dur-
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Table 4. Univariate and Adjusted Multivariate (Logistic-Regression) Analysis of Possible Predictors of Congenital CMV
Infection for the Prevention Group.*
Predictor

Infected Group

All women in the prevention group

Uninfected
Group

25

59

6 (24)

31 (52)

<21 weeks of gestation

14

43

≥21 weeks of gestation

11

16

Infants whose mothers received HIG — no. (%)

Univariate
P Value†

Multivariate
P Value‡

0.02

0.04

0.20

0.49

0.78

ND

0.62

ND

Time of primary infection — no. of women§

Maternal age at enrollment — yr
Median
Interquartile range

30

29

27–32

27–33

22

57

No. of primary infections
Identified by maternal screening

3

2

No. of infants whose mothers had a CMV-specific
increase in IgG by delivery/total no. tested

Identified by maternal symptoms

5/8

13/19

1.00

ND

No. of infants whose mothers had an increase in
CMV-specific IgG avidity by delivery/total
no. tested

8/8

19/19

1.00

ND

No. of infants whose mothers had an increase in
CMV-specific IgG after HIG by infusion/total no. tested

4/4

11/11

1.00

ND

No. of infants whose mothers had a decrease in natural killer cells by delivery/total no. tested

2/8

8/14

0.63

ND

6

31
0.08

0.75

4

5

3–5

4–6
0.08

0.59

0.78

ND

Women who received HIG
No. of HIG doses per woman
Median
Interquartile range
Wk of gestation for HIG administration
Median
Interquartile range
Time between maternal infection and HIG
administration — wk¶

23

18

20–27

15–22

6.7±1.9

6.6±2.8

* HIG denotes hyperimmune globulin, and ND not done.
† Either Fisher’s exact test or Wilcoxon’s rank-sum test was used for the univariate comparisons.
‡ Exact logistic regression was used for the multivariate comparison.
§ When the weeks of gestation at the time of maternal infection were known only as a range, the average of the end points
of the range was used to estimate the time of maternal infection.
¶ Plus–minus values are means ±SD.

ing pregnancy, reported rates of maternal-to-fetal
transmission range from 40 to 50 percent.1,3,4 Overall, transmission occurred among 56 percent of
women with a primary infection and 16 percent of
those receiving hyperimmune globulin.
The highest rate of symptomatic congenital infection and sequelae — about 25 percent — occurs
among infected infants whose mothers had a primary infection during pregnancy.19 The rate of CMV
disease among infected infants of seropositive

n engl j med 353;13

mothers is 8 percent or less.19 We observed CMV
disease in 28 percent of congenitally infected infants whose mothers did not receive hyperimmune
globulin. This rate is compatible with previous observations. Among the 37 congenitally infected infants of women who received hyperimmune globulin, only 1 (3 percent) had CMV disease.
Neonatal-transfusion studies first showed that
antibodies against CMV were protective against
CMV disease.20,21 Symptomatic CMV infections de-
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Table 5. CMV-Specific IgG Concentrations and CMV Avidity in Women before and after Hyperimmune Globulin (HIG)
Infusions, at Enrollment, and at Delivery.*
Group

No. of Women
CMV-Specific
with Results IgG Concentration

P Value†

No. of Women
with Results

CMV-Specific
IgG Avidity

P Value†

% high-avidity
antibodies

U/ml
Therapy group
Before HIG

10

5.5 (3.4–9.7)

After HIG

10

12.4 (8.0–19.0)

At enrollment

12

7.2 (5.0–11.4)

At delivery

12

17.4 (11.7–26.0)‡

<0.001
<0.001

13

11.1 (8.5–15.6)

13

24.8 (18.6–31.4)

12

6.7 (4.1–10.6)

12

32.5 (29.3–41.7)

15

15.1 (12.7–18.0)‡

15

25.1 (19.8–31.7)

<0.001
<0.001

Prevention group
Before HIG

9

6.9 (3.7–12.7)

After HIG

9

11.8 (7.5–18.5)

At enrollment

20

4.1 (2.8–6.1)

At delivery

20

11.7 (8.3–16.5)

At enrollment

17

6.6 (4.5–9.5)

At delivery

17

7.5 (4.9–11.4)

<0.001
<0.001

20

8.1 (5.5–12.0)

20

29.6 (24.1–36.3)

17

8.7 (6.2–12.1)

17

21.5 (15.3–30.1)

<0.001
<0.001

Untreated group
0.54

<0.001

* Values are geometric means (and 95 percent confidence intervals). HIG denotes hyperimmune globulin.
† P values were calculated with the use of a paired t-test on log-transformed data and are for the comparison of values
either before and after treatment or at enrollment and at delivery.
‡ P<0.006 for the comparison with the untreated group. All other comparisons of IgG concentrations and avidity between
the untreated group and the therapy and prevention groups either before or after treatment or at enrollment or delivery
were not significantly different (P>0.05).

veloped in premature newborns born to CMV-seronegative mothers after the receipt of blood products, whereas premature newborns born to CMVseropositive mothers became infected but remained
asymptomatic after receiving blood products. By
eight weeks of age, only 10 to 20 percent of maternal antibody against CMV remains. Even at this age,
newborns are protected against severe CMV disease.22 Impressive results have also been observed
in pregnant guinea pigs challenged with guineapig CMV before or after passive administration of
antiserum to either whole virus or to a specific
guinea-pig–CMV glycoprotein B that induces neutralizing antibodies.23,24
Because of the availability of serial serum samples from each subject, we could identify the time
of maternal infection for nearly all subjects to within an average range of six weeks. The majority of
women were infected in the first trimester (42 percent) or the second trimester (50 percent) of pregnancy. Thus, the possible efficacy of hyperimmune
globulin therapy for maternal infection in the last
trimester is uncertain. The infusion of hyperimmune globulin into amniotic fluid appeared ineffec-
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tive. The pregnant woman who delivered the only
symptomatic neonate among all 68 treated women
received both intraamniotic and intra–umbilicalcord hyperimmune globulin (Table 2).
Treatment with hyperimmune globulin decreased the number and percentage of both natural killer cells and HLA-DR+ cells, as compared with
these values among untreated women with active
CMV infection. This effect may be related to the
ability of hyperimmune globulin to inhibit the replication of CMV, since at the onset of a primary CMV
infection, the numbers of natural killer cells and
HLA-DR+ cells are increased.25,26 However, the increased number and activity of these immune cells
are associated with a high level of production of cytokines such as tumor necrosis factor a, which can
contribute to immune-mediated fetal damage.27,28
Thus, hyperimmune globulin may diminish the
pathogenic effects of CMV either by neutralization
or immunomodulatory effects.
Hyperimmune globulin appeared less effective
for the prevention of fetal infection than for the
treatment of fetuses already infected. Several factors may explain this finding. First, some of the six
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infected infants may have been infected before their
mothers received hyperimmune globulin. Second,
the prevention group received a lower dose of hyperimmune globulin than the therapy group, although it was administered monthly in the former
group to sustain antibody concentrations until delivery. Third and most likely is that the mechanism
of action of hyperimmune globulin differs in the
prevention and therapy groups. For the prevention
of fetal infection, hyperimmune globulin presumably reduces maternal systemic or placental viral
loads, thus decreasing the likelihood of fetal infection. Once the fetus is infected, however, hyperimmune globulin presumably reduces placental
or fetal inflammation, or both, resulting in increased
fetal blood flow with enhanced fetal nutrition and
oxygenation. This mechanism may also account
for the reversal of ultrasonographic abnormalities
apparently associated with hyperimmune globulin therapy, since most signs and symptoms of congenital infection usually resolve during the first
weeks of life, presumably owing to improved nutrition and oxygenation.
Serologic screening of asymptomatic women is
common in Europe but less so in the United States.
For our study, in 2000, we screened 1722 pregnant
women, 401 (23 percent) of whom were seronegative and 31 (2 percent) of whom subsequently seroconverted. In the United States, the seroconversion rate is similar.4,29 Whether serologic screening
during pregnancy is desirable remains undecided.
Cost–benefit ratios need to be considered. Ultrasonography of the fetus at 20 weeks’ gestation is,
however, routine in many countries, including the
United States. Our experience suggests this is a sen-

sitive approach for predicting congenital disease
due to CMV.
A limitation of our study was that it did not include random assignment. Our data should stimulate the initiation of randomized, controlled trials,
possibly in the United States or other countries
where maternal CMV screening is not routine, to
provide additional data and unequivocally establish the degree of efficacy of hyperimmune globulin therapy and the optimal doses and dosing regimens.
Although CMV-specific hyperimmune globulin
therapy was safe and appears to be associated with
both effective therapy and the prevention of congenital infection, passive immunization is not an
optimal solution. Our results indicate that active immunization is feasible. Several vaccines are being
evaluated in clinical trials, and a vaccine that induces only maternal antibodies against CMV should be
effective in this setting.30,31
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